Back to Agenda
China Townhall
Session Chair(s)
Fengyun (Vicky) Han
Senior Director, Head of Regulatory Policy for Asia Pacific
Johnson & Johnson Pte. Ltd., Singapore
Xiangyu Wang
Division Director, Department of Science, Technology & International Cooperation
NMPA, China
A New Era of Drug R&D in China China Regulatory Agency NMPA made a stride step in improving its regulatory environment and ecosystem since the introduction of the regulatory reform and becoming an ICH member and of the ICH Management Committee: the review timeline is reduced significantly, and the number of approved innovative medicines increased year by year, the drug lag issue has been resolved significantly. Now, NMPA has been moving to further implementation of ICH and contribution to ICH new guideline development, engaging as a formal member of PIC/s, and seeking regulatory modernization by leveraging new technology and data science into regulatory system and introducing of advanced emerging regulatory science and advanced regulatory measures in review farmwork, such as: RWE in regulatory decision making, Cell & Gene therapy (particularly CAR-T), Orphan Drugs, Patient Focused Drug Development, DCT, ePI and AI in drug R&D, pediatric drug development, etc. All these initiatives are embedded in an ecosystem to move forward for a new era of drug R&D in China. In this China townhall session, we will hear 2 speakers' from CDE and Tsing Hua University to give the in-person presentation, and follows a panel discussion, the panelist including speakers and additional panelist from CDE and industry to cover these hot topics.
Speaker(s)
![Tao Wang, MD, PhD](/_Images/member/Generic_Image_Missing-Profile.jpg)
The Evolution of Regulatory Modernization Development in China
Tao Wang, MD, PhD
China Food and Drug Administration (CFDA), China
Director of Chemical Medicine Evaluation office II
Globalization and Innovation of Drug Clinical Development in China-An Investigator's View
Xiaoyuan Chen, PhD
Beijing Tsinghua Changgung Hospital, China
Director, GCP Officer
Panelist
Zili Li, MD, MPH
Janssen Research & Development, China
Vice President, Head of Asia Pacific R&D
![Jiaqi Lu](/_Images/member/Generic_Image_Missing-Profile.jpg)
Panelist
Jiaqi Lu
CDE NMPA, China
Reviewer
Panelist
Xiaojun (Wendy) Yan, MD, MBA
BeiGene (Beijing) Co., Ltd., China
Senior Vice President, Chief Regulatory Officer
Panelist
Wei Zhang
Boehringer Ingelheim Shanghai Pharmaceuticals Co., Ltd., China
VP, Regional Head of Biometrics and Data Management, Asia/MENA
Panelist
Anette Hjelmsmark, MS
Novo Nordisk A/S, Denmark
Senior Regulatory Intelligence Manager
![Qing Chen](/_Images/member/Generic_Image_Missing-Profile.jpg)
Qing Chen
Taya Language, Belgium
Have an account?